Evaluation of the Therapeutic Pattern and Pharmaco-Utilization in Hypercholesterolemic Patients Treated with Statins: A Retrospective Study on Italian Real-World Data

References

• Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274:131–136. doi:10.1001/jama.1995.03530020049031
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Rev Esp Cardiol. 2017;70:115. doi:10.1016/j.rec.2017.01.002
   PubMedGoogle Scholar
• Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381. doi:10.1093/eurheartj/ehw106
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–1818. doi:10.1093/eurheartj/ehr158
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64:485–494. doi:10.1016/j.jacc.2014.02.615
   PubMed Web of Science ®Google Scholar
• Agabiti Rosei E, Salvetti M. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High Blood Press Cardiovasc Prev. 2016;23:217–230. doi:10.1007/s40292-016-0155-2
   PubMed Web of Science ®Google Scholar
• Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4:462–471. doi:10.1016/j.jacl.2010.08.026
   PubMed Web of Science ®Google Scholar
• Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65:1013–1024. doi:10.1007/s00228-009-0673-0
   PubMed Web of Science ®Google Scholar
• Pitts RN, Eckel RH. The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology. Eur Cardiol. 2014;9(2):65–70. doi:10.15420/ecr.2014.9.2.65
   PubMedGoogle Scholar
• Charlson ME. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Gazzetta Ufficiale Serie Generale n.113 del 04 maggio 2020. Modifica della Nota AIFA 13 di cui alla determina AIFA n. 2014. Available from: https://www.gazzettaufficiale.it/eli/gu/2020/05/04/113/sg/pdf. Accessed November 19, 2021.
   Google Scholar
• Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? PLoS One. 2014;9:e102146. doi:10.1371/journal.pone.0102146
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Tokgözoğlu L. Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. Atheroscler Suppl. 2019;39:100002.
   Google Scholar
• Morieri ML, Perrone V, Veronesi C, et al. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes. Cardiovasc Diabetol. 2021;20:14. doi:10.1186/s12933-021-01338-y
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64:485–494.
   PubMed Web of Science ®Google Scholar
• Presta V, Figliuzzi I, Miceli F, et al.; EFFECTUS Steering Committee. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: analysis of a large real practice database in Italy. Atherosclerosis. 2019;285:40–48. doi:10.1016/j.atherosclerosis.2019.03.017
   PubMed Web of Science ®Google Scholar
• Bruckert E, Parhofer KG, Gonzalez-Juanatey JR, et al. Proportion of high-risk/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review. Adv Ther. 2020;37:1724–1736. doi:10.1007/s12325-020-01285-2
   PubMed Web of Science ®Google Scholar
• Crismaru I, Pantea Stoian A, Bratu OG, et al. Low-density lipoprotein cholesterol lowering treatment: the current approach. Lipids Health Dis. 2020;19(1):85. doi:10.1186/s12944-020-01275-x
   PubMed Web of Science ®Google Scholar
• Corrao G, Conti V, Merlino L, Catapano AL, Mancia G. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther. 2010;32:300–310. doi:10.1016/j.clinthera.2010.02.004
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008;7:717–725. doi:10.1517/14740330802396984
   PubMed Web of Science ®Google Scholar
• OsMed 2020 National Report on medicines use in Italy. Available from: https://www.aifa.gov.it/en/-/rapporto-nazionale-osmed-2020-sull-uso-dei-farmaci-in-italia. Accessed: November, 19 2021.
   Google Scholar
• Dobrică EC, Găman MA, Cozma MA, et al. Polypharmacy in type 2 diabetes mellitus: insights from an Internal Medicine Department. Medicina. 2019;55:436. doi:10.3390/medicina55080436
   PubMed Web of Science ®Google Scholar